Aigenpulse Ltd, a company which employs data technologies and advanced machine learning to accelerate drug discovery has moved into larger premises at Milton Park, Oxfordshire and opened offices at the CIC in Boston, Massachusetts, US. The additional spaces support the company’s continued expansion, growing four-fold in the last year, including the appointment of Nick Cross as Non-Executive Director, and Dr Satnam Surae as Chief Product Officer.
Aigenpulse will take 2,026 sq ft in the science and technology cluster at Milton Park, Oxfordshire, one of Europe’s largest business parks, with plans to take additional space to accommodate future expansion.
The new office space at the CIC in Boston, Massachusetts, expands Aigenpulse’s presence in and support for the North America market. As part of the East Coast’s well-established life sciences cluster, the premises are part of the company’s plans to extend its global reach and to develop its US client base.
Tobias Kloepper, Chief Executive Officer at Aigenpulse, said: “The new office space in the UK and US is an exciting development for the company. Since launching in 2016 we have seen significant growth, specifically in response to customer recognition of the value we have created in the biotech sector. Therefore, as a fast-growing company, it is essential we are positioned in locations that offer us the flexibility to expand, whilst being surrounded with like-minded, innovative businesses, as Milton Park and the Boston life sciences cluster does.”
Philip Campbell, Commercial Director for MEPC at Milton Park, said: “We’re delighted that Aigenpulse has chosen to expand its operations here at Milton Park. The company is consistent with the kind of pioneering organisations Milton Park is already home to. And we look forward to supporting Tobias and his team with their future growth plans. They are a great addition to the life sciences cluster at Milton Park.”